YWYanfeng Wang

Yanfeng Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yanfeng Wang has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Zhenghao Huo

    Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China

    3 shared publications
  • Hong Zhu

    Department of Rheumatology, General Hospital of Ningxia Medical University, Yinchuan, China

    2 shared publications
  • Jie Dang

    Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China

    2 shared publications
  • Jing Zhang

    Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China

    2 shared publications
  • Pengfei Luan

    Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China

    2 shared publications
  • Qian Ma

    Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China

    2 shared publications

Latest Publications

  • The Cardiovascular Safety of Antiparkinsonian Drugs—Analysis of Signals in the FDA Adverse Event Report System Database

    by Xin Mu, Yanfeng Wang, Peiyao Wei, Junwei Ren, Pingping Ning

    Objective: This study aimed to investigate the characteristics and spectrum of cardiotoxicity induced by various antiparkinsonian drugs based on the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. Methods: Data from the FAERS database from the first quarter of 2004 to the third quarter of 2025 were downloaded for disproportionality analysis. We employed validated disproportionality metrics including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN) and multi‐item gamma Poisson shrinker (MGPS) to detect significant drug‐event associations. Results: After removing duplicates, a total of 42 583 cases of patients treated with antiparkinsonian drugs were included in the FAERS database. Dopamine receptor agonists exhibited the most extensive range of cardiac adverse events. Monoamine oxidase B inhibitors displayed the second broadest range of toxicity. As for catechol‐O‐methyltransferase inhibitors, a total of six signals were detected in entacapone. Four signals were detected for amantadine, while no signals were identified for levodopa. Conclusion: This study highlights the cardiovascular adverse reactions associated with Parkinson's treatment drugs. These findings underscore the importance of monitoring and evaluating the cardiovascular safety of antiparkinsonian medications.

  • Open Access

    Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients

    by Yiqun Li, Yanfeng Wang, Ning Li, Xinjun Liang, Shu Zhang, Qingxia Fan, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, et al.

    An abstract is unavailable. This article is available as a PDF only.


  • Open Access

    Corrigendum to “miR-183-5p Is a Potential Molecular Marker of Systemic Lupus Erythematosus”

    by Shaolan Zhou, Jing Zhang, Pengfei Luan, Zhanbing Ma, Jie Dang, Hong Zhu, Qian Ma, Yanfeng Wang, Zhenghao Huo

    [This corrects the article DOI: 10.1155/2021/5547635.].


  • Open Access

    Identification of hub genes, pathways, and related transcription factors in systemic lupus erythematosus

    by Yanfeng Wang, Qian Ma, Zhenghao Huo

    Background: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ damage and the production of a variety of autoantibodies. The pathogenesis of SLE has not been fully defined, and it is difficult to treat. Our study aimed to identify candidate genes that may be used as biomarkers for the screening, diagnosis, and treatment of SLE. Methods: We used the GEO2R tool to identify the differentially expressed genes (DEGs) in SLE-related datasets retrieved from the Gene Expression Omnibus (GEO). In addition, we also identified the biological functions of the DEGs by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. Additionally, we constructed protein–protein interaction (PPI) networks to identify hub genes, as well as the regulatory network of transcription factors related to DEGs. Results: Two datasets were identified for use from the GEO (GSE50772, GSE4588), and 34 up-regulated genes and 4 down-regulated genes were identified by GEO2R. Pathway analysis of the DEGs revealed enrichment of the interferon alpha/beta signaling pathway; GO analysis was mainly enriched in response to interferon alpha, regulation of ribonuclease activity. PPIs were constructed through the STRING database and 14 hub genes were selected and 1 significant module (score = 12.923) was obtained from the PPI network. Additionally, 11 key transcription factors that interacted closely with the 14 hub DEGs were identified from the gene transcription factor network. Conclusions: Bioinformatic analysis is an effective tool for screening the original genomic data in the GEO database, and a large number of SLE-related DEGs were identified. The identified hub DEGs may be potential biomarkers of SLE.


  • Open Access

    miR-183-5p Is a Potential Molecular Marker of Systemic Lupus Erythematosus

    by Shaolan Zhou, Jing Zhang, Pengfei Luan, Zhanbing Ma, Jie Dang, Hong Zhu, Qian Ma, Yanfeng Wang, Zhenghao Huo

    Objective. To investigate microRNA (miRNA) expression profiles in individuals with systemic lupus erythematosus (SLE) and identify the valuable miRNA biomarkers in diagnosing and monitoring SLE. Methods. Next-generation sequencing (NGS) was performed to assess miRNA amounts in peripheral blood mononuclear cells (PBMCs) from four SLE cases and four healthy controls. Quantitative polymerase chain reaction (qPCR) was carried out for validating candidate miRNAs in 32 SLE cases and 32 healthy controls. In addition, receiver operating characteristic (ROC) curve analysis was completed to evaluate diagnostic performance. Finally, the associations of candidate miRNAs with various characteristics of SLE were analyzed. Results. A total of 157 miRNAs were upregulated, and 110 miRNAs were downregulated in PBMCs from SLE cases in comparison to healthy controls, of which the increase of miR-183-5p and decrease of miR-374b-3p were validated by qPCR and both showed good diagnostic performance for SLE diagnosis. Besides, miR-183-5p expression levels displayed a positive association with SLE disease activity index (SLEDAI) and anti-dsDNA antibody amounts. Conclusion. Our data indicated that miR-183-5p is a promising biomarker of SLE.


  • Open Access

    miR‐149 Suppresses the Proliferation and Metastasis of Human Gastric Cancer Cells by Targeting FOXC1

    by Dan Li, Yunqing Zhang, Yulong Li, Xiaofei Wang, Fenghui Wang, Juan Du, Huahua Zhang, Haiyan Shi, Yanfeng Wang, Yi Gao, et al.

    Purpose. Gastric cancer is one of the most common cancers in the world. miRNAs play an important role in regulating gene expression by binding with 3 ′‐UTR of the target gene. The aim of this study was to investigate the function of miRNA‐149 and FOXC1 in gastric cancer. Patients and Methods. qRT‐PCR was used to detect the expression of miRNA‐149 and FOXC1 in gastric cancer tissues and cells. Human gastric cancer cell lines AGS and MKN28 were cultured and transfected with miR‐149 overexpression plasmid and its control or FOXC1 siRNA and its control. The MTT, colony formation, flow cytometry, wound healing, transwell, and western blotting were performed to examine the function of miRNA‐149 and FOXC1 in the development of gastric cancer. What is more, dual‐luciferase assay and western blotting were used to demonstrated the relationship between miRNA‐149 and FOXC1. Results. miRNA‐149 was underexpressed in gastric cancer tissues and cells, while overexpression of miRNA‐149 promoted cell apoptosis, retarded cell cycle, and inhibited proliferation and migration in AGS and MKN28 cells. In addition, we showed that miRNA‐149 targeted FOXC1. What is more, FOXC1 was highly expressed in gastric cancer tissues and cells; the silencing of FOXC1 inhibited the biological function of AGS and MKN28 cells. Conclusion. miRNA‐149 inhibits the biological behavior of gastric cancer by targeting FOXC1, providing a promising target in the treatment of human gastric cancer.